New data highlight potential benefit of SPINRAZA® (nusinersen) in infants and toddlers with unmet medical needs after gene therapy

/PRNewswire/ -- Ionis Pharmaceuticals (Nasdaq: IONS) today announced that its partner Biogen presented new data highlighting the potential benefit of SPINRAZA®...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,C Frank Bennett , ,Twitter ,Exchange Commission ,Biogen Inc ,Ionis Pharmaceuticals ,Ionis Pharmaceuticals Inc ,Research Clinical Care Meeting ,Prnewswire Ionis Pharmaceuticals Nasdaq ,Clinical Care Meeting ,Analysis Evaluating Real World Impact ,Important Safety Information ,Prescribing Information ,Nc ,